• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Recurrent Salmonella enterica Typhimurium infection disables host protection against intestinal inflammation [PreClinical]

byOmar ViramontesandRadhika Agarwal
February 4, 2018
in Chronic Disease, Infectious Disease, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Repeated gastrointestinal infections in mice, in this case Salmonella enterica Typhimurium (ST), caused intestinal tissue inflammation which escalated with repeated infections.

2. Increased turnover of intestinal alkaline phosphatase (IAP), related to increased endogenous neuraminidase activity among duodenal enterocytes, was found to be associated with inflammatory bowel disease (IBD). The administration of exogenous IAP or antiviral neuraminidase (Neu) inhibitor Zanavir maintained the IAP levels and prevented IBD onset.

Evidence Rating Level: 2 (Good)

Study Rundown: IBD, which includes both Crohn’s disease and ulcerative colitis (UC), is responsible for a significant disease burden and decreased quality of life across the world.  The mechanism underlying these diseases is not completely understood, though both genetic and environmental contributions appear to play a part.  Due to previously observed association in hospital admissions for IBD and hospital admissions for bacterial infections, this study explored whether initial and repeated GI infection with Salmonella enterica Typhimurium (ST) accelerated onset of IBD.  The study found that even months after cessation of Salmonella infection, inflammation persisted. This inflammation was related to an acquired deficiency of intestinal alkaline phosphatase (IAP), important in detoxifying LPS endotoxin by commensal microorganisms in the host. The deficiency in IAP was mediated by increased breakdown of IAP by Neuraminidase by enterocytes. Overall, the investigators found that both IAP augmentation and neuraminidase inhibition with zanamivir prevented LPS accumulation and provided a therapeutic approach to IBD. Further clinical trials will be necessary to show the efficacy of such treatments in human subjects. 

Click to read the study, published in Science Immunology

Relevant Reading:  Increased catabolism and decreased unsaturation of ganglioside in patients with inflammatory bowel disease

In-Depth [animal study]: The study found persistent inflammation after months of cessation of additional Salmonella infections.  The mechanism was an acquired deficiency of IAP, an enzyme produced by the enterocytes of the intestine.  IAP is responsible for dephosphorylating and detoxifying the lipopolysaccharide (LPS) endotoxin produced by many GI commensal bacteria. Salmonella infection was found to increase endogenous neuraminidase (Neu) activity among enterocytes by a Toll-like receptor 4 (TLR4) dependent mechanism.  Increased Neu activity was related to increased turnover of IAP, increasing LPS phosphate levels in the intestine, contributing to the inflammation.  This study used a murine model C57BL/6J, TLR4–/– and control mice to simulate foodborne GI infections. They used low-titer and nonlethal gastrointestinal infections of a virulent ST virus.  To induce chronic colitis, 8-week-old mice were chronically infected 5 times every 4 weeks with ST (2 x 103 cfu).  Colitis was assessed biweekly with weight and colitis symptoms of diarrhea, stool consistency, fecal blood and rectal prolapse. In repeated ST infections, inflammatory cytokines mRNA expression levels of chemokine ligand 5 (CCL5) (p<0.001), interleukin-1β (IL-1β) (p<0.001), tumor necrosis factor-α (TNF-α) (p<0.001) and interferon-Îł (IFN-Îł) (p<0.001) were significantly increased in the colon.  Also, histologically, there was a significant increase in infiltration of leukocytes (p<0.001) into the lamina propria, including neutrophils, monocytes and T cells, reduction of goblet cells (p<0.01) and erosion of the epithelial barrier (p<0.001). Administration of calf IAP (cIAP) significantly maintained IAP activity levels in the intestinal tract compared to those with recurrent ST infections (p<0.001). Zanamivir administration resulted in maintenance of normal IAP activity levels in animals with ST infections (p<0.01).  Overall, IAP augmentation or Neu inhibition may represent novel candidate therapies that can be used for the treatment of colitis induced by Salmonella infections.

RELATED REPORTS

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Crohn's DiseasesalmonellaUlcerative Colitis
Previous Post

Catheter ablation of atrial fibrillation in heart failure reduces mortality and hospitalization: The CASTLE-AF trial

Next Post

Improved islet encapsulation device for the treatment of type 1 diabetes [PreClinical]

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

September 14, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

August 11, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

June 14, 2022
Next Post

Improved islet encapsulation device for the treatment of type 1 diabetes [PreClinical]

AAP reaffirms support for adolescents’ rights to confidential reproductive care

Transgender, gender nonconforming youths underutilize health care

AAP policy statement discusses recommended immunizations

AAP policy statement discusses recommended immunizations

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options